3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Myeloid
1
Conditions
Carcinoma, Non-Small-Cell Lung
3
Small Cell Lung Carcinoma
2
Prostatic Neoplasms
2
Neoplasms
2
Lung Neoplasms
2
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
2
Glioblastoma
2
Brain Neoplasms
2
Adenocarcinoma of Lung
2
Urinary Bladder Neoplasms
1
Solid Tumor
1
Peripheral Nervous System Diseases
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Ovarian Neoplasms
1
Oligodendroglioma
1
Neoplasms by Histologic Type
1
Neoplasm Metastasis
1
NSCLC
1
Myeloproliferative Disorders
1
Lymphoma, T-Cell, Cutaneous
1
Leukemia, Myeloid, Chronic-Phase
1
Leukemia, Myeloid, Acute
1
Leukemia, Myeloid
1
Leukemia
1
Hematologic Diseases
1
Head and Neck Neoplasms
1
Glioma
1
Gastrointestinal Stromal Tumors
1
Carcinoma, Hepatocellular
1
Breast Neoplasms
1
Interventions
ruxolitinib
21
Azacitidine
5
ponatinib
4
parsaclisib
4
nilotinib
4
itacitinib
4
anagrelide
3
Phlebotomy
3
Imatinib Mesylate
3
INCB039110
3
Aspirin
3
11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene
3
venetoclax
2
pemigatinib
2
luspatercept
2
imetelstat
2
givinostat hydrochloride
2
givinostat
2
fedratinib
2
asciminib
2
INCB057643
2
Gemcitabine
2
GRN163L peptide
2
spartalizumab
1
sonidegib
1
selinexor
1
sabatolimab
1
rucaparib
1
pembrolizumab
1
navitoclax
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Myeloproliferative Disorders
×
BID protein, human
×
Clear all
NCT02627677
2021-11-26
OPTIC-2L
Takeda
Phase 3
Terminated
44 enrolled
22 charts